Income Statement

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Condensed Consolidated Statements Of Operations        
PRODUCT REVENUE, NET $ 48,966 $ 61,279 $ 59,400 $ 116,611
COST OF REVENUE, PRODUCT 42,400 52,443 60,158 90,389
GROSS (LOSS) MARGIN 6,566 8,836 (758) 26,222
EXPENSES        
Sales and marketing 111,393 45,496 455,437 65,061
General and administrative 188,052 84,619 395,198 223,516
Depreciation and Amortization 292 56,128 585 112,256
TOTAL OPERATING EXPENSES 299,737 186,243 851,220 400,833
OPERATING LOSS (293,171) (177,407) (851,978) (374,611)
Other Income (Expense)        
Unrealized gain on equity investments 245,834 404,763
Interest Expense (66,422) (68,301)
Total other income, net 179,412 336,462
NET LOSS (113,759) (177,407) (515,516) (374,611)
Less: Net loss (income) attributable to non controlling interest 3,336 57 9,592 (1,139)
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (110,423) $ (177,350) $ (505,924) $ (375,750)
LOSS PER COMMON SHARE $ (0.01) $ (0.01) $ (0.05) $ (0.02)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and diluted 10,677,110 15,320,154 10,617,332 15,268,914

Source